Researchers have
found that
women with advanced cervical
cancer live
about four months longer with the combined use of bevacizumab and chemotherapy
compared to chemotherapy alone.
Women who combined bevacizumab with chemotherapy lived an average of 17 months after diagnosis, while those who received chemotherapy alone lived 13.3 months.
Dr. Bradley J Monk, nationally recognized for his expertise incervical cancer and chairs the Gynecologic Oncology Cervical Cancer Committee for the National Cancer Institute funded Gynecologic Oncology Group, and the project's senior author said that this research proves that there are new options for patients with metastatic cervical cancer.
Women who combined bevacizumab with chemotherapy lived an average of 17 months after diagnosis, while those who received chemotherapy alone lived 13.3 months.
Dr. Bradley J Monk, nationally recognized for his expertise incervical cancer and chairs the Gynecologic Oncology Cervical Cancer Committee for the National Cancer Institute funded Gynecologic Oncology Group, and the project's senior author said that this research proves that there are new options for patients with metastatic cervical cancer.
No comments:
Post a Comment